Literature DB >> 33453067

From NAFLD to MAFLD: Nurse and allied health perspective.

Michelle Clayton1, Núria Fabrellas2, Jinkai Luo3, Mohammed G Alghamdi4, Azaa Hafez5, Tahani Al Qadiri6, Nevin Owise7, Dina Attia8.   

Abstract

Fatty liver disease associated with metabolic dysfunction is the most prevalent liver disease worldwide, though both patient and health professional still lack awareness of it. An international consensus panel has produced what is sure to be an influential report renaming the disease from non-alcoholic fatty liver disease (NAFLD) to metabolic (dysfunction) associated fatty liver disease (MAFLD) and suggesting how the disease should be diagnosed. This viewpoint explores the call from the perspective of nurse and allied health practitioners. This group have raised serious concerns on the existing nomenclature, which labels the disease as NAFLD, and its diagnostic criteria, including provoking nurse role confusion and representing a major barrier to various key aspects; patient-nurse communications, patient awareness, partnership working, motivation of patients to undertake lifestyle changes and multiple health behaviour change promotion and nurse-led clinics. Therefore, they are enthusiastically supportive of this call to reframe the disease that we believe will ultimately have a positive impact on nurse-patient communication, and through this, improve patient care and quality of life and reduce burden on health system.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  MAFLD; NAFLD; nurse

Year:  2021        PMID: 33453067     DOI: 10.1111/liv.14788

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  10 in total

1.  Metabolic (dysfunction) associated fatty liver disease: more evidence and a bright future.

Authors:  Ting-Yao Wang; Jacob George; Ming-Hua Zheng
Journal:  Hepatobiliary Surg Nutr       Date:  2021-12       Impact factor: 7.293

2.  Annual Meeting of the Canadian Association for the Study of the Liver (CASL), the Canadian Network on Hepatitis C (CanHepC), the Canadian Association of Hepatology Nurses (CAHN), and the Canadian NASH Network 2022 Abstracts.

Authors: 
Journal:  Can Liver J       Date:  2022-05-09

3.  Relationship between the Metabolic Associated Fatty Liver Disease and Endometrial Thickness in Postmenopausal Women: A Cross-sectional Study in China.

Authors:  Jia-Ying Wei; Zhou Xu; Hao Li; Wen-Qin Du; Bai-Ling Niu; Shu Li; Shen Tian; Juan Wu; Yu-Ling Chen; Xin Li; Zi-Li Liu; Jun Xiao; Guo-Sheng Ren; Liang Ran; Ling-Quan Kong
Journal:  Int J Med Sci       Date:  2021-06-22       Impact factor: 3.738

Review 4.  Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science.

Authors:  Yasser Fouad; Melissa Palmer; Minjun Chen; Arie Regev; Rajarshi Banerjee; Rob Myers; Robert Riccio; Richard Torstenson; Ramy Younes; Puneet S Arora; Henrik Landgren; Morten A Karsdal; Martin Blake; David A Shapiro; Hans-Juergen Gruss; Muhammad Y Sheikh; Dina Attia; Steven Bollipo; Alastair D Smith; Bradley Freilich; Robert G Gish; Detlef Schuppan
Journal:  J Clin Transl Hepatol       Date:  2021-10-22

5.  Metabolic-associated Fatty Liver Disease.

Authors:  Ming-Hua Zheng
Journal:  J Clin Transl Hepatol       Date:  2021-11-09

Review 6.  Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update.

Authors:  Jawaher Alharthi; Mohammed Eslam
Journal:  J Clin Transl Hepatol       Date:  2021-10-13

7.  Comparing the Diagnostic Criteria of MAFLD and NAFLD in the Chinese Population: A Population-based Prospective Cohort Study.

Authors:  Cheng Yu; Minzhen Wang; Shan Zheng; Miao Xia; Hongyan Yang; Desheng Zhang; Chun Yin; Ning Cheng; Yana Bai
Journal:  J Clin Transl Hepatol       Date:  2021-07-01

Review 8.  MAFLD enhances clinical practice for liver disease in the Asia-Pacific region.

Authors:  Takumi Kawaguchi; Tsubasa Tsutsumi; Dan Nakano; Mohammed Eslam; Jacob George; Takuji Torimura
Journal:  Clin Mol Hepatol       Date:  2021-11-10

9.  Editorial: The Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD) and Non-Alcoholic Fatty Liver Disease (NAFLD) Debate: Why the American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) Consensus Process is Not Representative.

Authors:  Yasser Mahrous Fouad; Ahmed Gomaa; Rasha Mohamed El Etreby; Mohamed AbdAllah; Dina Attia
Journal:  Med Sci Monit       Date:  2022-08-22

10.  Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD).

Authors:  Nahum Méndez-Sánchez; Luis Enrique Díaz-Orozco
Journal:  Med Sci Monit       Date:  2021-07-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.